Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Newron Pharmaceuticals SpA (NWRN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.00 0.00    0.00%
16:31:00 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  IT0004147952 
VALOR:  2791431
  • Volume: 43,337
  • Bid/Ask: 6.87 / 7.00
  • Day's Range: 6.85 - 7.18
Newron Pharmaceuticals 7.00 0.00 0.00%

Newron Pharmaceuticals SpA Company Profile

 
Get an in-depth profile of Newron Pharmaceuticals SpA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

23

Equity Type

ORD

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Contact Information

Address Via Antonio Meucci 3
Bresso, 20091
Italy
Phone 39 02 610 3461
Fax 39 02 610 34654

Top Executives

Name Age Since Title
Marco Onofrj - - Member of Scientific Advisory Board
Luca Benatti 62 1998 Non-Executive & Independent Director
Fabrizio Stocchi - - Member of Scientific and Clinical Advisory Board
Paolo Marchettini - - Member of Scientific & Clinical Advisory Board
Charles Warren Olanow - - Member of Scientific Advisory Board
Richard Paul Murphy 58 2002 Chairman of the Board of Statutory Auditors
Abraham Lieberman - - Member of Scientific Advisory Board
Emilio Perucca - - Member of Scientific & Clinical Advisory Board
Ulrich Köstlin 70 2013 Independent Non-Executive Chairman
Ze’ ev Seltzer - - Member of Scientific & Clinical Advisory Board
Stefan Weber 57 2005 CEO & Executive Director
William Langston - - Member of Scientific Advisory Board
Patrick J. Langlois 77 2008 Independent Non-Executive Director
Gillian Dines - 2023 Non-Executive Director
Massimo Giaconia 64 2013 Member of the Board of Statutory Auditors
Lucio Giulio Ricci 55 2002 Member of the Board of Statutory Auditors
Margarita I. Chavez - 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NWRN Comments

Write your thoughts about Newron Pharmaceuticals SpA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email